CA2419979A1 - Mammalian genes; related reagents and methods - Google Patents

Mammalian genes; related reagents and methods Download PDF

Info

Publication number
CA2419979A1
CA2419979A1 CA002419979A CA2419979A CA2419979A1 CA 2419979 A1 CA2419979 A1 CA 2419979A1 CA 002419979 A CA002419979 A CA 002419979A CA 2419979 A CA2419979 A CA 2419979A CA 2419979 A1 CA2419979 A1 CA 2419979A1
Authority
CA
Canada
Prior art keywords
leu
ser
pro
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002419979A
Other languages
English (en)
French (fr)
Inventor
Christi L. Parham
Daniel M. Gorman
Hirokazu Kurata
Naoko Arai
Theodore R. Sana
Jeanine D. Mattson
Erin E. Murphy
Chetan Savkoor
Jeffery Grein
Kathleen M. Smith
Terrill K. Mcclanahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2419979A1 publication Critical patent/CA2419979A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002419979A 2000-09-08 2001-09-07 Mammalian genes; related reagents and methods Abandoned CA2419979A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23126700P 2000-09-08 2000-09-08
US60/231,267 2000-09-08
PCT/US2001/028013 WO2002020569A2 (en) 2000-09-08 2001-09-07 Mammalian genes; related reagents and methods

Publications (1)

Publication Number Publication Date
CA2419979A1 true CA2419979A1 (en) 2002-03-14

Family

ID=22868480

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002419979A Abandoned CA2419979A1 (en) 2000-09-08 2001-09-07 Mammalian genes; related reagents and methods

Country Status (9)

Country Link
US (6) US7060800B2 (enExample)
EP (2) EP1315743B1 (enExample)
JP (2) JP2004509617A (enExample)
CN (1) CN1452633A (enExample)
AT (1) ATE549347T1 (enExample)
AU (1) AU2001294541A1 (enExample)
CA (1) CA2419979A1 (enExample)
MX (1) MXPA03002049A (enExample)
WO (1) WO2002020569A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1235845A4 (en) * 1999-11-05 2003-06-25 Human Genome Sciences Inc 24 HUMAN SECRETED PROTEINS
AU2253301A (en) 1999-12-03 2001-06-12 Zymogenetics Inc. Human cytokine receptor
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
EP1337636B1 (en) 2000-08-08 2006-10-18 ZymoGenetics, Inc. Soluble zcytor 11 cytokine receptors
US7358353B2 (en) * 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
US20030166526A1 (en) 2000-08-22 2003-09-04 Challita-Eid Pia M. Nucleic acid and corresponding protein named 158P1H4 useful in the treatment and detection of bladder and other cancers
WO2002020569A2 (en) * 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
DK1356046T3 (da) * 2000-11-28 2010-03-01 Zymogenetics L L C Cytokinreceptor zcytoR19
CA2430257A1 (en) * 2000-11-28 2002-06-06 Amgen, Inc. Transforming growth factor-beta-related molecules and uses thereof
AU2002252460A1 (en) 2001-03-27 2002-10-08 Zymogenetics, Inc. Human cytokine receptor
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
WO2003031620A1 (en) * 2001-10-02 2003-04-17 Mochida Pharmaceutical Co., Ltd. Novel class ii cytokine receptor
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
US7265211B2 (en) 2002-03-22 2007-09-04 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of making
EP1497415B1 (en) 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Methods for detection or modulation of the interaction of a cytokine receptor with its ligand
US7141381B2 (en) 2002-04-25 2006-11-28 Bristol-Myers Squibb Company Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
PT1941867E (pt) 2002-06-07 2012-02-16 Dyax Corp Polipeptídeo contendo um domínio kunitz modificado
EP1575609A4 (en) 2002-10-23 2010-12-15 Zymogenetics L L C METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1594892A2 (en) * 2003-02-10 2005-11-16 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
KR20050116392A (ko) 2003-03-24 2005-12-12 지모제넥틱스, 인코포레이티드 항-ｉｌ-22ｒａ 항체 및 결합 파트너 및 염증에 있어서의사용 방법
WO2005023862A2 (en) 2003-08-07 2005-03-17 Zymogenetics, Inc. Homogeneous preparations of il-28 and il-29
PT1663281E (pt) * 2003-08-29 2014-03-17 Dyax Corp Inibidores de proteases poli-peguilados
GB0325038D0 (en) * 2003-10-27 2003-12-03 Ares Trading Sa Protein
US20050244423A1 (en) 2004-04-02 2005-11-03 Klucher Kevin M Methods for treating viral infection using IL-28 and IL-29 cysteine mutants
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2006012644A2 (en) 2004-07-29 2006-02-02 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
GB0423973D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa C1q related points
CA2603671C (en) * 2005-04-26 2012-03-27 Laboratoires Serono S.A. Insp163 polypeptides for the treatment or prevention of cancer and arthritis
JP4987001B2 (ja) 2005-07-20 2012-07-25 ザイモジェネティクス リミテッド ライアビリティ カンパニー 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
CN101641094A (zh) * 2007-04-11 2010-02-03 爱尔康研究有限公司 TNFα抑制剂联合抗组胺药治疗变应性鼻炎和变应性结膜炎的用途
DK2915564T3 (da) 2007-09-28 2021-02-08 Alexion Pharma Inc Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
CN102625712B (zh) 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法
BR112012007091A2 (pt) * 2009-10-01 2016-04-19 Alcon Res Ltd composições de olopatadina e seus usos
WO2013016449A2 (en) 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
KR102143887B1 (ko) 2012-03-16 2020-08-12 유니버시티 헬스 네트워크 Toso 활성을 조절하기 위한 방법 및 조성물
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102355959B1 (ko) 2012-08-23 2022-01-27 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
HK1255383A1 (zh) 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
AU2018206552C1 (en) 2017-01-04 2025-04-10 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
EP3565834B1 (en) 2017-01-04 2025-10-22 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CN110229226B (zh) * 2019-05-23 2023-04-11 西安医学院 一种slfn11截断肽及其应用和药物组合物
US12209118B2 (en) 2019-07-08 2025-01-28 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US88426A (en) 1869-03-30 Improved velocipede
US2736896A (en) 1951-12-04 1956-02-28 Sperry Rand Corp Horn antenna system
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
WO2002020569A2 (en) * 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
US11068393B2 (en) 2019-10-17 2021-07-20 Microsoft Technology Licensing, Llc Enhanced concurrency garbage collection stack scanning

Also Published As

Publication number Publication date
US7060800B2 (en) 2006-06-13
US20090155242A1 (en) 2009-06-18
US20050186620A1 (en) 2005-08-25
US8426573B2 (en) 2013-04-23
US20100104576A1 (en) 2010-04-29
WO2002020569A3 (en) 2003-01-23
US7427668B2 (en) 2008-09-23
EP1315743B1 (en) 2012-11-07
US7696317B2 (en) 2010-04-13
JP2004509617A (ja) 2004-04-02
EP2298789A1 (en) 2011-03-23
EP1315743A2 (en) 2003-06-04
WO2002020569A2 (en) 2002-03-14
US20020142292A1 (en) 2002-10-03
US7893211B2 (en) 2011-02-22
JP2009039124A (ja) 2009-02-26
AU2001294541A1 (en) 2002-03-22
US8148507B2 (en) 2012-04-03
ATE549347T1 (de) 2012-03-15
US20110165165A1 (en) 2011-07-07
US20120164147A1 (en) 2012-06-28
CN1452633A (zh) 2003-10-29
EP2298789B1 (en) 2012-03-14
MXPA03002049A (es) 2003-07-24

Similar Documents

Publication Publication Date Title
CA2419979A1 (en) Mammalian genes; related reagents and methods
CA2410083A1 (en) Mammalian receptor proteins; related reagents and methods
CA2408571A1 (en) Mammalian receptor proteins; related reagents and methods
WO1999040195A1 (en) Mammalian receptor proteins; related reagents and methods
CA2392109A1 (en) Mammalian receptor proteins; related reagents and methods
CA2374391A1 (en) Mammalian receptor proteins; related reagents and methods
EP1062332A2 (en) Human receptor proteins; related reagents and methods
US7812126B2 (en) DIRS1 polypeptides
US20030082734A1 (en) Mammalian receptor proteins; related reagents and methods
CA2372549A1 (en) Ox2 receptor homologs
CA2306455A1 (en) Human receptor proteins; related reagents and methods

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued